**5/9/2024**

**Supplementary Materials for Article: DNA Methylation-Derived Immune Cell Proportions and Cancer Risk, Including Lung Cancer, in Black Participants**

Authors: Christopher S. Semancik, M.P.H., B.S.1, Naisi Zhao, M.S., Dr.PH1, Devin C. Koestler, Ph.D.2,3, Eric Boerwinkle, Ph.D.4,5, Jan Bressler, Ph.D.4, Rachel J. Buchsbaum, M.D.6, Karl T. Kelsey, M.D., M.O.H.7,8, Elizabeth A. Platz, Sc.D, M.P.H.9,10, Dominique S. Michaud, Sc.D.1

**Author Affiliations:**

1Department of Public Health & Community Medicine, Tufts University School of Medicine, Tufts University, Boston, MA, USA

2The University of Kansas Cancer Center, Kansas City, KS, USA

3Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA

4Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA

5Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA

6Division of Hematology/Oncology, Tufts Medical Center, Boston, MA, USA

7Department of Epidemiology, Brown University, Providence, RI, USA

8Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA

9Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

10The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

**Corresponding Author:**

Dominique S. Michaud, ScD

Tufts University School of Medicine

136 Harrison Avenue

Boston, MA 02111

Tel: ​617-636-0482

Email: [Dominique.Michaud@tufts.edu](mailto:Dominique.Michaud@tufts.edu)

**Keywords:** DNA methylation, immune cell profiles, deconvolution, immunology, epidemiology

Supplementary Table 1: HRs for Sensitivity Analysis Including Diabetes and Educational Statuses:

HR b (95% CI) per 1 percent increase in methylation-derived immune cell proportion or 1 unit increase in ratios or white blood cell count

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methylation-Derived Immune Cell Type or Measure | All Cancer a  (668 cases) | Lung Cancer  (84 cases) | Postmenopausal Breast Cancer c  (114 cases) | Prostate Cancer d  (173 cases) |
| CD4+ | 0.99 (0.98, 1.01) | 0.99 (0.96, 1.03) | 1.00 (0.97, 1.02) | 1.00 (0.98, 1.03) |
| CD4+ memory | 0.99 (0.98, 1.01) | 0.99 (0.95, 1.03) | 1.01 (0.98, 1.05) | 1.00 (0.97, 1.03) |
| CD4+ naïve | 1.00 (0.98, 1.02) | 1.00 (0.95, 1.06) | 0.97 (0.93, 1.02) | 1.01 (0.96, 1.05) |
| CD4+ naïve-to-memory ratio | 1.02 (0.99, 1.05) | 0.97 (0.85, 1.10) | 1.00 (0.93, 1.08) | 0.97 (0.89, 1.06) |
| CD8+ | 1.00 (0.99, 1.01) | 1.02 (0.99, 1.06) | 1.01 (0.98, 1.05) | 1.01 (0.99, 1.04) |
| CD8+ memory | 1.00 (0.99, 1.02) | 1.03 (1.00, 1.06) | 1.02 (0.99, 1.05) | 1.01 (0.99, 1.03) |
| CD8+ naïve | 0.96 (0.91, 1.01) | 0.85 (0.71, 1.01) | 0.96 (0.86, 1.08) | 0.99 (0.89, 1.11) |
| CD8+ naïve-to-memory ratio | 0.98 (0.87, 1.09) | 0.89 (0.60, 1.09) | 0.97 (0.75, 1.25) | 0.82 (0.61, 1.11) |
| CD4+-to-CD8+ ratio | 0.97 (0.91, 1.03) | 0.99 (0.85, 1.17) | 0.90 (0.75, 1.08) | 0.93 (0.81, 1.06) |
| Treg | 1.06 (1.00, 1.12) | **1.21 (1.05, 1.40)** | 1.04 (0.92, 1.18) | 1.09 (0.96, 1.23) |
| B cell | 0.99 (0.97, 1.02) | 0.98 (0.91, 1.07) | 1.04 (0.98, 1.10) | 0.97 (0.92, 1.03) |
| B cell memory | **1.13 (1.05, 1.21)** | 1.18 (0.97, 1.44) | 0.95 (0.73, 1.23) | **1.18 (1.05, 1.33)** |
| B cell naïve | 0.98 (0.95, 1.01) | 0.96 (0.88, 1.05) | 1.05 (0.99, 1.07) | 0.94 (0.89, 1.00) |
| B cell naïve-to-memory ratio | 0.99 (0.98, 1.00) | 0.97 (0.94, 1.00) | 1.02 (1.00, 1.04) | 0.98 (0.96, 1.00) |
| NLR | 1.00 (0.98, 1.02) | 0.94 (0.86, 1.03) | 0.99 (0.94, 1.04) | 1.01 (0.97, 1.04) |
| Lymphocyte to Monocyte Ratio | 1.00 (1.00, 1.00) | 1.00 (1.00, 1.00) | 1.00 (1.00, 1.00) | 1.03 (0.95, 1.13) |
| White blood cell count (from CBC differential) | 1.02 (0.98, 1.07)  (n = 659) | **1.18 (1.05, 1.32)**  (n = 83) | 1.04 (0.93, 1.17)  (n = 112) | 0.99 (0.90, 1.08)  (n = 171) |

a Excluding hematologic cancers. b Multivariable models were adjusted for age, sex, BMI, self-reported smoking status, self-reported smoking pack-years, postmenopausal hormone use (creating an ‘NA’ category for males), methylation-derived smoking pack-years, mdNLR (in all models except mdNLR and lymphocyte to monocyte ratio), diabetes status, educational status, and batch effect. c The breast cancer model also adjusted for self-reported drinking status and did not adjust for sex. d The prostate cancer model did not adjust for sex or postmenopausal hormone use (men only).

Supplementary Table 2: HRs for Time-Lag Analysis:

HR b (95% CI) per 1 percent increase in methylation-derived immune cell proportion or 1 unit increase in ratios or white blood cell count

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methylation-Derived Immune Cell Type or Measure | All Cancer b  (625 cases) | Lung Cancer  (79 cases) | Postmenopausal Breast Cancer c  (106 cases) | Prostate Cancer d  (163 cases) |
| CD4+ | 1.00 (0.98, 1.01) | 1.00 (0.96, 1.04) | 1.00 (0.97, 1.03) | 1.00 (0.98, 1.03) |
| CD4+ memory | 0.99 (0.98, 1.01) | 1.00 (0.95, 1.05) | 1.02 (0.98, 1.05) | 1.00 (0.97, 1.03) |
| CD4+ naïve | 1.00 (0.98, 1.02) | 1.00 (0.95, 1.06) | 0.97 (0.93, 1.02) | 1.00 (0.96, 1.05) |
| CD4+ naïve-to-memory ratio | 1.02 (0.98, 1.05) | 0.96 (0.84, 1.09) | 0.99 (0.91, 1.08) | 0.96 (0.88, 1.05) |
| CD8+ | 1.00 (0.99, 1.01) | 1.03 (1.00, 1.07) | 1.01 (0.98, 1.04) | 1.01 (0.99, 1.03) |
| CD8+ memory | 1.00 (0.99, 1.02) | 1.04 (1.00, 1.07) | 1.02 (0.99, 1.05) | 1.01 (0.99, 1.03) |
| CD8+ naïve | 0.95 (0.90, 1.01) | 0.86 (0.72, 1.02) | 0.95 (0.84, 1.07) | 1.00 (0.89, 1.12) |
| CD8+ naïve-to-memory ratio | 0.97 (0.87, 1.09) | 0.89 (0.60, 1.32) | 0.93 (0.70, 1.23) | 0.83 (0.61, 1.14) |
| CD4+-to-CD8+ ratio | 0.98 (0.92, 1.05) | 0.99 (0.85, 1.15) | 0.90 (0.75, 1.09) | 0.94 (0.82, 1.08) |
| Treg | 1.06 (1.00, 1.12) | **1.25 (1.08, 1.44)** | 1.04 (0.91, 1.18) | 1.12 (0.98 (1.26) |
| B cell | 1.00 (0.97, 1.03) | 0.99 (0.91, 1.07) | 1.04 (0.98, 1.11) | 0.98 (0.93, 1.04) |
| B cell memory | **1.14 (1.06, 1.23)** | 1.21 (1.00, 1.48) | 0.95 (0.72, 1.24) | **1.19 (1.05, 1.34)** |
| B cell naïve | 0.98 (0.96, 1.01) | 0.96 (0.88, 1.05) | 1.05 (0.99, 1.11) | 0.95 (0.90, 1.01) |
| B cell naïve-to-memory ratio | 0.99 (0.98, 1.00) | 0.97 (0.94, 1.01) | 1.02 (0.99, 1.04) | 0.98 (0.96, 1.01) |
| NLR | 1.00 (0.98, 1.02) | 0.94 (0.85, 1.03) | 0.99 (0.94, 1.04) | 1.03 (0.99, 1.06) |
| Lymphocyte to Monocyte Ratio | 1.00 (1.00, 1.00) | 1.00 (1.00, 1.00) | 1.00 (1.00, 1.00) | 1.00 (0.88, 1.13) |
| White blood cell count (from CBC differential) | 1.02 (0.98, 1.07)  (n = 616) | **1.20 (1.07, 1.34)**  (n = 78) | 1.04 (0.92, 1.17)  (n = 104) | 0.98 (0.89, 1.07)  (n = 161) |

a Excluding hematologic cancers. b To assess the possibility of reverse causation, individuals with less than two years of follow-up were excluded from this analysis, regardless of whether they were a case of cancer or lost to follow-up within two years. Multivariable models were adjusted for age, sex, BMI, self-reported smoking status, self-reported smoking pack-years, postmenopausal hormone use (creating an ‘NA’ category for males), methylation-derived smoking pack-years, mdNLR (in all models except mdNLR and lymphocyte to monocyte ratio), and batch effect. c The breast cancer model also adjusted for self-reported drinking status and did not adjust for sex. d The prostate cancer model did not adjust for sex or postmenopausal hormone use (men only).

Supplementary Table 3: HRs for Quartile Analysis in All Cancers a:

HR a (95% CI) for each quartile of methylation-derived immune cell proportion or 1 unit increase in ratios or white blood cell count

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Quartile | | | |  | |
| Methylation-Derived Immune Cell  Type or Measure | Quartile 1 HR  (95% CI) | Quartile 2 HR  (95% CI) | Quartile 3 HR  (95% CI) | Quartile 4 HR  (95% CI) | | p-trend |
| CD4+ | Ref.  (n = 182) | 0.88 (0.70, 1.10)  (n = 165) | 0.89 (0.71, 1.12)  (n = 168) | 0.89 (0.70, 1.13)  (n = 153) | | 0.33 |
| CD4+ memory | Ref.  (n = 175) | 0.93 (0.74, 1.16)  (n = 161) | 0.90 (0.71, 1.13)  (n = 173) | 0.87 (0.68, 1.11)  (n = 159) | | 0.26 |
| CD4+ naïve | Ref.  (n = 181) | 0.92 (0.74, 1.14)  (n = 166) | 0.96 (0.77, 1.20)  (n = 167) | 0.98 (0.78, 1.24)  (n = 154) | | 0.99 |
| CD4+ naïve-to-memory ratio | Ref.  (n = 168) | 1.15 (0.93, 1.42)  (n = 173) | 0.96 (0.76, 1.21)  (n = 152) | 1.21 (0.96, 1.52)  (n = 175) | | 0.30 |
| CD8+ | Ref.  (n = 180) | 1.01 (0.81, 1.26)  (n = 161) | 0.92 (0.73, 1.15)  (n = 154) | 1.05 (0.83, 1.31)  (n = 173) | | 0.83 |
| CD8+ memory | Ref.  (n = 178) | 0.97 (0.78, 1.21)  (n = 166) | 0.83 (0.66, 1.05)  (n = 146) | 1.05 (0.84, 1.31)  (n = 178) | | 0.49 |
| CD8+ naïve | Ref.  (n = 322) | 1.02 (0.83, 1.25)  (n = 134) | 0.80 (0.64, 1.01)  (n = 105) | 0.83 (0.66, 1.04)  (n = 107) | | 0.09 |
| CD8+ naïve-to-memory ratio | Ref.  (n = 182) | 0.95 (0.77, 1.17)  (n = 172) | 0.83 (0.67, 1.03)  (n = 153) | 0.87 (0.69, 1.09)  (n = 161) | | 0.67 |
| CD4+-to-CD8+ ratio | Ref.  (n = 196) | **0.74 (0.60, 0.91)**  (n = 150) | **0.76 (0.61, 0.94)**  (n = 154) | 0.85 (0.69, 1.06)  (n = 168) | | 0.39 |
| Treg | Ref.  (n = 201) | **1.30 (1.03, 1.64)**  (n = 114) | 1.24 (1.00, 1.53)  (n = 166) | **1.31 (1.04, 1.65)**  (n = 187) | | 0.05 |
| B cell | Ref.  (n = 177) | 0.83 (0.66, 1.04)  (n = 156) | 0.89 (0.71, 1.11)  (n = 170) | 0.93 (0.74, 1.18)  (n = 165) | | 0.61 |
| B cell memory | Ref.  (n = 496) | 0.73 (0.53, 1.01)  (n = 40) | 1.16 (0.88, 1.53)  (n = 60) | **1.47 (1.13, 1.91)**  (n = 72) | | 0.001 |
| B cell naïve | Ref.  (n = 187) | **0.79 (0.63, 0.98)**  (n = 165) | **0.77 (0.61, 0.96)**  (n = 161) | **0.79 (0.62, 0.99)**  (n = 155) | | 0.14 |
| B cell naïve-to-memory ratio | Ref.  (n = 186) | 0.91 (0.74, 1.12)  (n = 181) | **0.76 (0.61, 0.96)**  (n = 150) | 0.81 (0.64, 1.02)  (n = 151) | | 0.08 |
| NLR | Ref.  (n = 154) | 1.00 (0.80, 1.25)  (n = 159) | 1.08 (0.87, 1.34)  (n = 177) | 1.14 (0.91, 1.42)  (n = 178) | | 0.96 |
| Lymphocyte to Monocyte Ratio | Ref.  (n = 177) | 0.90 (0.73, 1.12)  (n = 161) | 1.09 (0.88, 1.35)  (n = 174) | 1.01 (0.80, 1.26)  (n = 156) | | 0.81 |
| White blood cell count (from CBC  differential) | Ref.  (n = 165) | 1.04 (0.83, 1.31)  (n = 149) | 1.16 (0.94, 1.45)  (n = 174) | 1.15 (0.92, 1.44)  (n = 171) | | 0.21 |

a Excluding hematologic cancers. Multivariable models were adjusted for age, sex, BMI, self-reported smoking status, self-reported smoking pack-years, methylation-derived smoking pack-years, postmenopausal hormone use, mdNLR, and batch effect.

Supplementary Table 4: HRs for Tertile Analysis in Lung Cancer:

HR (95% CI) for each tertile of methylation-derived immune cell proportion or 1 unit increase in ratios or white blood cell count

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Tertile | | |  |
| Methylation-Derived Immune Cell  Type or Measure | Tertile 1 HR  (95% CI) | Tertile 2 HR  (95% CI) | Tertile 3 HR  (95% CI) | p-trend |
| CD4+ | Ref.  (n = 22) | 1.60 (0.90, 2.85)  (n = 38) | 1.10 (0.57, 2.14)  (n = 24) | 0.81 |
| CD4+ memory | Ref.  (n = 22) | 1.42 (0.80, 2.52)  (n = 38) | 0.83 (0.42, 1.63)  (n = 24) | 0.79 |
| CD4+ naïve | Ref.  (n = 34) | 0.70 (0.41, 1.20)  (n = 24) | 0.97 (0.56, 1.69)  (n = 26) | 0.98 |
| CD4+ naïve-to-memory ratio | Ref.  (n = 35) | 0.76 (0.44, 1.31)  (n = 24) | 1.10 (0.62, 1.93)  (n = 25) | 0.56 |
| CD8+ | Ref.  (n = 31) | 0.84 (0.48, 1.47)  (n = 25) | 1.03 (0.59, 1.79)  (n = 28) | 0.16 |
| CD8+ memory | Ref.  (n = 26) | 1.28 (0.74, 2.22)  (n = 31) | 1.27 (0.71, 2.27)  (n = 27) | 0.06 |
| CD8+ naïve | Ref.  (n = 46) | 0.67 (0.40, 1.13)  (n = 23) | **0.47 (0.25, 0.87)**  (n = 15) | 0.06 |
| CD8+ naïve-to-memory ratio | Ref.  (n = 34) | 0.87 (0.52, 1.46)  (n = 28) | 0.57 (0.32, 1.01)  (n = 22) | 0.49 |
| CD4+-to-CD8+ ratio | Ref.  (n = 35) | **0.54 (0.31, 0.94)**  (n = 20) | 0.73 (0.44, 1.22)  (n = 29) | 0.82 |
| Treg | Ref.  (n = 20) | 1.26 (0.69, 2.28)  (n = 26) | 1.42 (0.77, 2.63)  (n = 38) | 0.01 |
| B cell | Ref.  (n = 27) | 0.83 (0.47, 1.46)  (n = 27) | 0.99 (0.56, 1.77)  (n = 30) | 0.66 |
| B cell memory | Ref.  (n = 54) | 1.27 (0.68, 2.36)  (n = 14) | 1.56 (0.84, 2.89)  (n = 16) | 0.60 |
| B cell naïve | Ref.  (n = 30) | 0.81 (0.47, 1.39)  (n = 29) | 0.74 (0.41, 1.32)  (n = 25) | 0.29 |
| B cell naïve-to-memory ratio | Ref.  (n = 37) | 0.77 (0.46, 1.30)  (n = 27) | **0.53 (0.29, 0.97)**  (n = 20) | 0.06 |
| NLR | Ref.  (n = 19) | **1.78 (1.01, 3.14)**  (n = 35) | 1.17 (0.64, 2.12)  (n = 30) | 0.21 |
| Lymphocyte to Monocyte Ratio | Ref.  (n = 26) | 1.53 (0.91, 2.57)  (n = 34) | 1.29 (0.72, 2.33)  (n = 24) | 0.99 |
| White blood cell count (from CBC  differential) | Ref.  (n = 15) | 1.73 (0.91, 3.27)  (n = 28) | **2.67 (1.43, 4.97)**  (n = 40) | 0.002 |

Multivariable models were adjusted for age, sex, BMI, self-reported smoking status, self-reported smoking pack-years, methylation-derived smoking pack-years, postmenopausal hormone use, mdNLR, and batch effect.

Supplementary Table 5: HRs for Tertile Analysis in Postmenopausal Breast Cancer:

HR (95% CI) for each tertile of methylation-derived immune cell proportion or 1 unit increase in ratios or white blood cell count

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Tertile | | |  |
| Methylation-Derived Immune Cell  Type or Measure | Tertile 1 HR  (95% CI) | Tertile 2 HR  (95% CI) | Tertile 3 HR  (95% CI) | p-trend |
| CD4+ | Ref.  (n = 33) | 0.97 (0.59, 1.58)  (n = 40) | 0.85 (0.51, 1.41)  (n = 41) | 0.78 |
| CD4+ memory | Ref.  (n = 37) | 0.84 (0.50, 1.39)  (n = 32) | 1.08 (0.65, 1.79)  (n = 45) | 0.41 |
| CD4+ naïve | Ref.  (n = 33) | 1.02 (0.64, 1.63)  (n = 44) | 0.72 (0.44, 1.20)  (n = 37) | 0.18 |
| CD4+ naïve-to-memory ratio | Ref.  (n = 41) | 0.71 (0.45, 1.15)  (n = 34) | 0.76 (0.47, 1.23)  (n = 39) | 0.95 |
| CD8+ | Ref.  (n = 41) | 0.66 (0.40, 1.07)  (n = 30) | 0.93 (0.59, 1.47)  (n = 43) | 0.34 |
| CD8+ memory | Ref.  (n = 42) | **0.61 (0.37, 0.99)**  (n = 27) | 1.10 (0.71, 1.72)  (n = 45) | 0.21 |
| CD8+ naïve | Ref.  (n = 62) | **0.36 (0.20, 0.63)**  (n = 16) | **0.64 (0.41, 0.99)**  (n = 36) | 0.47 |
| CD8+ naïve-to-memory ratio | Ref.  (n = 45) | **0.60 (0.37, 0.96)**  (n = 28) | 0.73 (0.46, 1.15)  (n = 41) | 0.76 |
| CD4+-to-CD8+ ratio | Ref.  (n = 34) | 1.09 (0.70, 1.72)  (n = 46) | 0.83 (0.51, 1.36)  (n = 34) | 0.23 |
| Treg | Ref.  (n = 34) | 0.75 (0.44, 1.28)  (n = 25) | 1.49 (0.92, 2.43)  (n = 55) | 0.51 |
| B cell | Ref.  (n = 29) | 0.85 (0.51, 1.43)  (n = 34) | 1.14 (0.70, 1.86)  (n = 51) | 0.22 |
| B cell memory | Ref.  (n = 94) | 0.44 (0.19, 1.01)  (n = 6) | 1.20 (0.65, 2.19)  (n = 14) | 0.72 |
| B cell naïve | Ref.  (n = 25) | 1.05 (0.61, 1.78)  (n = 36) | 1.40 (0.84, 2.34)  (n = 53) | 0.17 |
| B cell naïve-to-memory ratio | Ref.  (n = 30) | 0.82 (0.49, 1.36)  (n = 33) | 1.12 (0.68, 1.84)  (n = 51) | 0.18 |
| NLR | Ref.  (n = 42) | 0.97 (0.62, 1.51)  (n = 38) | 1.02 (0.65, 1.61)  (n = 34) | 0.70 |
| Lymphocyte to Monocyte Ratio | Ref.  (n = 27) | 0.96 (0.57, 1.61)  (n = 33) | 1.31 (0.81, 2.09)  (n = 54) | 0.84 |
| White blood cell count (from CBC  differential) | Ref.  (n = 36) | 1.10 (0.70, 1.75)  (n = 40) | 1.22 (0.75, 1.98)  (n = 36) | 0.37 |

Multivariable models were adjusted for BMI, self-reported smoking status, self-reported smoking pack-years, methylation-derived smoking pack-years, self-reported drinking status, postmenopausal hormone use, mdNLR, and batch effect.

Supplementary Table 6: HRs for Tertile Analysis in Prostate Cancer:

HR (95% CI) for each tertile of methylation-derived immune cell proportion or 1 unit increase in ratios or white blood cell count

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Tertile | | |  |
| Methylation-Derived Immune Cell  Type or Measure | Tertile 1 HR  (95% CI) | Tertile 2 HR  (95% CI) | Tertile 3 HR  (95% CI) | p-trend |
| CD4+ | Ref.  (n = 68) | 1.08 (0.74, 1.57)  (n = 59) | 1.10 (0.74, 1.65)  (n = 46) | 0.69 |
| CD4+ memory | Ref.  (n = 59) | 1.19 (0.81, 1.75)  (n = 62) | 1.13 (0.74, 1.72)  (n = 52) | 0.95 |
| CD4+ naïve | Ref.  (n = 75) | 0.85 (0.59, 1.22)  (n = 53) | 1.02 (0.70, 1.51)  (n = 45) | 0.56 |
| CD4+ naïve-to-memory ratio | Ref.  (n = 64) | 1.13 (0.79, 1.64)  (n = 60) | 0.95 (0.64, 1.41)  (n = 49) | 0.61 |
| CD8+ | Ref.  (n = 56) | 1.25 (0.84, 1.87)  (n = 53) | 1.40 (0.95, 2.06)  (n = 64) | 0.31 |
| CD8+ memory | Ref.  (n = 57) | 1.06 (0.71, 1.59)  (n = 49) | 1.24 (0.85, 1.82)  (n = 67) | 0.38 |
| CD8+ naïve | Ref.  (n = 84) | **1.47 (1.05, 2.07)**  (n = 60) | 0.89 (0.57, 1.38)  (n = 29) | 0.98 |
| CD8+ naïve-to-memory ratio | Ref.  (n = 63) | 1.21 (0.86, 1.72)  (n = 67) | 0.79 (0.52, 1.20)  (n = 43) | 0.24 |
| CD4+-to-CD8+ ratio | Ref.  (n = 71) | 0.87 (0.60, 1.24)  (n = 53) | 0.84 (0.58, 1.22)  (n = 49) | 0.35 |
| Treg | Ref.  (n = 55) | **1.59 (1.10, 2.31)**  (n = 66) | 1.34 (0.87, 2.06)  (n = 52) | 0.20 |
| B cell | Ref.  (n = 81) | 0.83 (0.57, 1.20)  (n = 50) | 0.87 (0.59, 1.29)  (n = 42) | 0.32 |
| B cell memory | Ref.  (n = 127) | 0.76 (0.45, 1.30)  (n = 16) | 1.27 (0.83, 1.95)  (n = 30) | 0.01 |
| B cell naïve | Ref.  (n = 85) | 0.77 (0.54, 1.11)  (n = 51) | 0.70 (0.47, 1.06)  (n = 37) | 0.06 |
| B cell naïve-to-memory ratio | Ref.  (n = 85) | **0.68 (0.47, 0.98)**  (n = 50) | 0.72 (0.48, 1.08)  (n = 38) | 0.10 |
| NLR | Ref.  (n = 55) | 0.96 (0.66, 1.40)  (n = 56) | 0.91 (0.63, 1.31)  (n = 62) | 0.59 |
| Lymphocyte to Monocyte Ratio | Ref.  (n = 71) | 1.12 (0.79, 1.59)  (n 60) | 1.16 (0.79, 1.71)  (n = 42) | 0.47 |
| White blood cell count (from CBC  differential) | Ref.  (n = 66) | 1.12 (0.78, 1.63)  (n = 56) | 0.95 (0.64, 1.40)  (n = 49) | 0.80 |

Multivariable models were adjusted for BMI, self-reported smoking status, self-reported smoking pack-years, methylation-derived smoking pack-years, mdNLR, and batch effect.

Supplementary Table 7: HRs for Sensitivity Analysis Including Total Leukocyte Count in All Cancers a and Lung Cancer:

HR b (95% CI) per 1 percent increase in methylation-derived immune cell proportion or 1 unit increase in ratios or white blood cell count

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Cancer Type | | | |
|  | All Cancers | | Lung Cancer | |
| Methylation-Derived Immune Cell Type or Measure | With WBC in Model  (659 cases) | Without WBC in Model  (668 cases) | With WBC in Model  (83 cases) | Without WBC in Model  (84 cases) |
| CD4+ naïve-to-memory ratio | 1.02 (0.98, 1.05) | 1.02 (0.99, 1.05) | 0.95 (0.83, 1.09) | 0.96 (0.85, 1.09) |
| CD8+ naïve | 0.96 (0.91, 1.01) | 0.95 (0.90, 1.01) | 0.85 (0.71, 1.01) | 0.85 (0.71, 1.01) |
| CD8+ naïve-to-memory ratio | 0.98 (0.88, 1.09) | 0.97 (0.87, 1.09) | 0.85 (0.57, 1.26) | 0.87 (0.59, 1.29) |
| CD4+-to-CD8+ ratio | 0.97 (0.91, 1.04) | 0.98 (0.92, 1.05) | 0.96 (0.82, 1.13) | 0.98 (0.84, 1.15) |
| Treg | 1.06 (1.00, 1.12) | 1.06 (1.00, 1.12) | **1.22 (1.06, 1.41)** | **1.22 (1.06, 1.41)** |
| B cell memory | **1.13 (1.05, 1.22)** | **1.13 (1.05, 1.22)** | **1.24 (1.02, 1.50)** | 1.20 (0.99, 1.46) |

a Excluding hematologic cancers. This model performed a sensitivity analysis to assess whether white blood cell count was independent of other relevant immune cell type proportions and measures. b Multivariable models were adjusted for sex, BMI, self-reported smoking status, self-reported smoking pack-years, methylation-derived smoking pack-years, postmenopausal hormone use, mdNLR, white blood cell count, and batch effect.

Supplementary Table 8: HRs for Sex-Stratified Model in All Cancers a:

HR b (95% CI) per 1 percent increase in methylation-derived immune cell proportion or 1 unit increase in ratios or white blood cell count

|  |  |  |  |
| --- | --- | --- | --- |
|  | Sex | |  |
| Methylation-Derived Immune Cell  Type or Measure | Females  (343 cases) | Males  (325 cases) | p-value for interaction |
| CD4+ | 0.99 (0.97, 1.00) | 1.00 (0.98, 1.02) | 0.25 |
| CD4+ memory | 0.99 (0.97, 1.01) | 0.99 (0.97, 1.02) | 0.48 |
| CD4+ naïve | 0.99 (0.97, 1.01) | 1.01 (0.98, 1.04) | 0.31 |
| CD4+ naïve-to-memory ratio | 1.03 (0.99, 1.07) | 0.98 (0.92, 1.05) | 0.13 |
| CD8+ | 0.99 (0.97, 1.01) | 1.01 (0.99, 1.02) | 0.12 |
| CD8+ memory | 1.00 (0.98, 1.02) | 1.01 (0.99, 1.02) | 0.19 |
| CD8+ naïve | 0.96 (0.90, 1.02) | 0.95 (0.87, 1.04) | 0.63 |
| CD8+ naïve-to-memory ratio | 0.98 (0.85, 1.14) | 0.97 (0.82, 1.16) | 0.61 |
| CD4+-to-CD8+ ratio | 0.98 (0.90, 1.07) | 0.97 (0.88, 1.05) | 0.71 |
| Treg | 1.06 (0.99, 1.14) | 1.03 (0.95, 1.13) | 0.08 |
| B cell | 1.01 (0.97, 1.04) | 0.97 (0.93, 1.01) | 0.22 |
| B cell memory | 1.09 (0.97, 1.22) | **1.16 (1.05, 1.28)** | 0.22 |
| B cell naïve | 1.00 (0.96, 1.03) | **0.95 (0.91, 0.99)** | 0.05 |
| B cell naïve-to-memory ratio | 1.00 (0.98, 1.01) | 0.98 (0.97, 1.00) | 0.08 |
| NLR | 1.00 (0.97, 1.02) | 1.00 (0.97, 1.03) | 0.67 |
| Lymphocyte to Monocyte Ratio | 1.00 (1.00, 1.00) | 1.02 (0.96, 1.10) | 0.29 |
| White blood cell count (from CBC  differential) | **1.09 (1.02, 1.16)**  (n = 337) | 0.98 (0.92, 1.05)  (n = 322) | 0.01 |

a Excluding hematologic cancers. b Multivariable models were adjusted for BMI, age, self-reported smoking status, self-reported smoking pack-years, methylation-derived smoking pack-years, mdNLR, post-menopausal hormone status (for women only), and batch effect.

Supplementary Table 9: HRs for Sex-Stratified Model in Lung Cancer:

HR (95% CI) per 1 percent increase in methylation-derived immune cell proportion or 1 unit increase in ratios or white blood cell count

|  |  |  |  |
| --- | --- | --- | --- |
|  | Sex | |  |
| Methylation-Derived Immune Cell Type or Measure | Females  (37 cases) | Males  (47 cases) | p-value for  interaction |
| CD4+ | 0.99 (0.93, 1.04) | 1.01 (0.96, 1.06) | 0.22 |
| CD4+ memory | 0.99 (0.93, 1.06) | 1.01 (0.95, 1.07) | 0.22 |
| CD4+ naïve | 0.98 (0.91, 1.06) | 1.02 (0.94, 1.11) | 0.67 |
| CD4+ naïve-to-memory ratio | 0.90 (0.75, 1.08) | 1.01 (0.82, 1.24) | 0.85 |
| CD8+ | 0.99 (0.93, 1.06) | 1.04 (1.00, 1.08) | 0.16 |
| CD8+ memory | 1.01 (0.95, 1.07) | 1.04 (1.00, 1.08) | 0.21 |
| CD8+ naïve | 0.88 (0.71, 1.09) | 0.77 (0.57, 1.06) | 0.26 |
| CD8+ naïve-to-memory ratio | 0.84 (0.49, 1.42) | 0.91 (0.52, 1.61) | 0.74 |
| CD4+-to-CD8+ ratio | 0.99 (0.77, 1.26) | 0.99 (0.81, 1.21) | 0.99 |
| Treg | 1.13 (0.93, 1.37) | 1.16 (0.92, 1.45) | 0.01 |
| B cell | 0.93 (0.82, 1.05) | 1.02 (0.91, 1.13) | 0.92 |
| B cell memory | 1.10 (0.78, 1.53) | **1.34 (1.04, 1.71)** | 0.19 |
| B cell naïve | 0.92 (0.81, 1.05) | 0.97 (0.84, 1.09) | 0.59 |
| B cell naïve-to-memory ratio | 0.95 (0.91, 1.00) | 0.97 (0.93, 1.02) | 0.50 |
| NLR | 0.91 (0.77, 1.07) | 0.98 (0.89, 1.09) | 0.76 |
| Lymphocyte to Monocyte Ratio | 1.00 (1.00, 1.00) | 1.08 (0.91, 1.29) | 0.19 |
| White blood cell count (from CBC differential) | **1.31 (1.09, 1.58)**  (n = 36) | 1.09 (0.94, 1.26)  (n = 47) | 0.12 |

Multivariable models were adjusted for BMI, age, self-reported smoking status, self-reported smoking pack-years, methylation-derived smoking pack-years, mdNLR, post-menopausal hormone status (for women only), and batch effect.

Supplementary Figure 1: All Cancer Spline Plots:

A graph with a line

Description automatically generated

A graph with a line

Description automatically generated with medium confidence

These spline plots assess the changes in the hazard ratios at various proportions of Tregs and CD8+ cells in all cancers. The P for nonlinear for Tregs of 0.143 and P for nonlinear of 0.787 for CD8+ cells indicates that a linear model is likely an appropriate means of representing these associations.

Supplementary Figure 2: Lung Cancer Spline Plots:

A graph of a line

Description automatically generated with medium confidence

A graph of a line

Description automatically generated with medium confidence

These spline plots assess the changes in the hazard ratios at various proportions of Tregs and CD8+ cells in lung cancer. The P for nonlinear for Tregs of 0.174 and P for nonlinear of 0.215 for CD8+ cells indicates that a linear model is likely an appropriate means of representing these associations.

Supplementary Figure 3: Postmenopausal Breast Cancer Spline Plots:

A graph of a graph

Description automatically generated with medium confidence

A graph of a person

Description automatically generated with medium confidence

These spline plots assess the changes in the hazard ratios at various proportions of Tregs and CD8+ cells in breast cancer. The P for nonlinear for Tregs of 0.002 and P for nonlinear of 0.588 for CD8+ cells call into question the appropriateness of a linear model for assessing this particular relationship.

Supplementary Figure 4: Prostate Cancer Spline Plots:

A graph of a person

Description automatically generated with medium confidence

A graph of a person with a blue line

Description automatically generated with medium confidence

These spline plots assess the changes in the hazard ratios at various proportions of Tregs and CD8+ cells in prostate cancer. The P for nonlinear for Tregs of 0.294 and P for nonlinear of 0.070 for CD8+ cells indicates that a linear model is likely an appropriate means of representing these associations.